Adicet Bio Board Shake-Up: Director Resigns, Grissinger Takes Committee Roles

Adicet Bio (NASDAQ:ACET) has reported changes to its board of directors, according to a regulatory filing covered by Investing.com. A director has resigned, the board has shrunk by one seat, and an existing director has taken on two new committee responsibilities. For traders who follow small-cap biotech, governance changes like these are routine disclosures worth understanding, even when they are not directly tied to clinical or financial results.

Key takeaways

• Director Andrew Sinclair, Ph.D., resigned from the board and from two committees, effective Friday.
• The board's size was reduced from seven to six members.
• Existing director Michael Grissinger joined the Audit Committee and became chair of the Nominating and Corporate Governance Committee.
• The filing, as reported, does not describe any change to the company's drug pipeline or financial outlook.

What changed at Adicet Bio

According to the report, Sinclair, a Class III director, told the company on Wednesday that he was stepping down. He left the board, the Audit Committee and the Nominating and Corporate Governance Committee. The resignation took effect on Friday, and the board went from seven members to six.

On the same day, the board followed a recommendation from the Nominating and Corporate Governance Committee and appointed Grissinger to the Audit Committee. The board determined that he meets the independence requirements for audit committee members under Nasdaq listing standards and the Securities Exchange Act of 1934. Grissinger was also named chair of the Nominating and Corporate Governance Committee.

Background: who is involved

Sinclair first joined the board in March 2021. At that time he was also placed on the same two committees and named chair of the Nominating and Corporate Governance Committee, according to the company's earlier SEC filing. Grissinger is a more recent addition. Adicet announced his appointment to the board in April 2025, noting his long career in pharmaceutical business development and strategic planning.

Adicet describes itself as a biotechnology company developing gamma delta T cell therapies for cancer and autoimmune diseases. The Audit Committee oversees matters such as financial reporting and auditor relationships, so changes to its membership are closely read by governance-focused investors.

Market context

The news is company-specific and arrived late on a Friday, so it is unlikely to be driving broad market moves. Wider risk sentiment was soft at the time of writing, with Bitcoin at 68,134.01, down 4.53% on the day, and NVIDIA at 162.85, down 2.01%. In currencies, EUR/USD was at 1.10280, down 0.28%. No live price for ACET was available in our data, so we cannot say how the shares reacted.

What to watch next

• Whether Adicet files further details or announces any plan to fill the vacant seat.
• How ACET shares trade when US markets reopen, since the news came after the close on Friday.
• Any commentary from the company on its pipeline or upcoming clinical updates, which typically matter more to biotech valuations than board housekeeping.

Markets are volatile, prices can move quickly in either direction, and this article is for education only and is not investment advice.